Your Patients Are Having Trouble Finding Myfembree — Here's How to Help

You've prescribed Estradiol/Norethindrone/Relugolix (Myfembree) for a patient with symptomatic uterine fibroids or endometriosis, and now they're calling your office saying they can't find it. This scenario is increasingly common, and it doesn't have to derail treatment.

Myfembree is not in a formal drug shortage — the manufacturing and supply chain are intact. The access challenges are structural: specialty medication classification, high acquisition cost ($1,300–$1,700/month), near-universal prior authorization requirements, and limited retail pharmacy stocking.

This guide provides five concrete steps your practice can take to help patients fill their Myfembree prescriptions, along with alternatives to consider and workflow tips to prevent access delays. For a broader overview of the availability landscape, see our provider shortage briefing.

Current Availability Landscape

Understanding where Myfembree is and isn't available helps you guide patients to the right pharmacy:

• Major chain pharmacies (CVS, Walgreens, Rite Aid): Rarely stock Myfembree on shelves. Will order upon confirmed prescription, typically 1–2 business day turnaround.
• Specialty pharmacies (CVS Specialty, Accredo, AllianceRx Walgreens, Optum Specialty): Routinely stock Myfembree. Most reliable source for consistent access.
• Independent pharmacies: Variable — some that serve OB/GYN practices may stock it. Generally willing to order with short turnaround.
• Mail-order specialty: Available through most insurance plans. Convenient for established patients on maintenance therapy.

Why Patients Can't Find It

When patients report they "can't find" Myfembree, the root causes typically fall into these categories:

1. Pharmacy doesn't stock it: The most common issue. Retail pharmacies manage inventory by demand, and low-volume specialty drugs don't make the cut.
2. Prior authorization not completed: Many pharmacies won't order a high-cost drug until insurance approval is confirmed. If prior authorization is pending or denied, the prescription sits unfilled.
3. Insurance directs to specialty pharmacy: The patient's plan may require dispensing through a specific specialty pharmacy, but neither the patient nor the retail pharmacy is aware of this restriction.
4. Cost shock: Patients who discover the $1,300–$1,700 cash price at the pharmacy may abandon the prescription, assuming they can't afford it — often without knowing about copay assistance programs.

What Providers Can Do: 5 Actionable Steps

Step 1: Initiate Prior Authorization at the Point of Prescribing

Don't wait for the pharmacy to trigger the prior authorization process. Start it immediately when you decide to prescribe Myfembree.

• Use electronic prior authorization (ePA) through your EHR if available — this can reduce turnaround from days to hours
• Document the clinical justification upfront: diagnosis, symptom severity, previous treatments tried and failed
• Include relevant imaging or lab results that support the medical necessity

Proactive prior authorization is the single most impactful step you can take to prevent fill delays.

Step 2: Direct Prescriptions to Specialty Pharmacies

When writing the prescription, identify the patient's insurance-designated specialty pharmacy and send it there directly.

• Check the patient's insurance card or contact the plan to determine the preferred specialty pharmacy
• Common specialty pharmacies for Myfembree: CVS Specialty, Accredo (Express Scripts), AllianceRx Walgreens, Optum Specialty
• Specialty pharmacies have dedicated teams for prior authorization support and can often facilitate the process alongside your office

Step 3: Enroll Patients in Financial Assistance Before the First Fill

Connect every eligible patient with financial support programs at the point of prescribing — not after they've experienced cost shock at the pharmacy.

• Myfembree Copay Assistance Program: Commercially insured patients may pay as little as $5 per monthly fill (up to $5,000 annual savings). Enrollment at myfembree.com/cost-and-support
• Myovant Patient Assistance Program: For uninsured or underinsured patients experiencing financial hardship
• Discount cards: GoodRx, SingleCare, and others can reduce cash prices to approximately $1,200–$1,560/month for uninsured patients

For a comprehensive list of savings options to share with patients, see saving money on Estradiol/Norethindrone/Relugolix.

Step 4: Use Medfinder to Identify Pharmacies With Stock

Medfinder for Providers allows you to check real-time pharmacy availability for Myfembree in your patient's area. This can be used by:

• Your prescribing staff when writing the initial prescription
• Patient coordinators when following up on unfilled prescriptions
• Patients themselves at medfinder.com

Knowing which pharmacy has stock before sending the prescription prevents the most common point of failure.

Step 5: Provide Patients With a Backup Plan

Set expectations with patients at the prescribing visit:

• Explain that Myfembree is a specialty medication that may not be at their usual pharmacy
• Give them the name of the specialty pharmacy their prescription is being sent to
• Provide information about the copay assistance program
• Let them know approximately how long prior authorization may take
• Discuss what to do if there's a delay — including when to call your office

Alternative Medications When Myfembree Isn't Accessible

For patients who cannot access Myfembree due to cost, insurance restrictions, or persistent availability issues, consider these alternatives:

• Oriahnn (Elagolix/Estradiol/Norethindrone Acetate) — Similar mechanism; approved for uterine fibroids only; twice-daily dosing
• Orilissa (Elagolix) — GnRH antagonist for endometriosis pain; no built-in add-back (can prescribe separately)
• Lupron Depot (Leuprolide Acetate) — Injectable GnRH agonist for fibroids and endometriosis; typically shorter treatment courses
• Levonorgestrel IUD (Mirena, Liletta) — First-line for heavy menstrual bleeding; cost-effective; long-acting but doesn't shrink fibroids

See the full comparison in our alternatives guide.

Workflow Tips for Your Practice

Incorporating these steps into your practice workflow can minimize Myfembree access issues:

Create a Specialty Medication Protocol

Develop a standard protocol for prescribing Myfembree (and other specialty medications) that includes:

1. Checking insurance coverage and specialty pharmacy designation at the scheduling stage
2. Initiating prior authorization at the prescribing visit
3. Enrolling the patient in copay assistance before they leave the office
4. Sending the prescription to the appropriate specialty pharmacy
5. Following up within 3–5 business days to confirm the prescription has been filled

Designate a Point Person

Assign a medical assistant, nurse, or patient coordinator as the point person for specialty medication prescriptions. This person can manage prior authorizations, financial assistance enrollment, and pharmacy coordination, reducing the burden on the prescriber.

Track Prior Authorization Status

Use your EHR's task tracking or a simple spreadsheet to monitor the status of pending prior authorizations. Follow up on any that haven't been approved within 3–5 business days.

Educate Patients Proactively

Consider creating a patient handout specifically for Myfembree that covers:

• What to expect with the pharmacy process
• How to use the copay card
• Specialty pharmacy contact information
• When and how to refill
• Your office contact for prescription issues

Final Thoughts

Estradiol/Norethindrone/Relugolix (Myfembree) access challenges are solvable with proactive practice-level interventions. By initiating prior authorization early, routing prescriptions to specialty pharmacies, connecting patients with financial assistance, and using tools like Medfinder for Providers, you can significantly reduce the number of patients who experience treatment delays.

For information on helping patients with medication costs, see our provider's guide to saving patients money on Estradiol/Norethindrone/Relugolix.